FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma
Last Updated: Tuesday, August 22, 2023
Accelerated approval was granted to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Advertisement
News & Literature Highlights